The natriuretic peptides system in the pathophysiology of heart failure: From molecular basis to treatment

Clinical Science

Volumn 130, Issue 2, 2016, Pages 57-77

  Volpe, Massimo ^a,b   Carnovali, Marino ^c   Mastromarino, Vittoria ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b IRCCS NEUROMED   (Italy)

^c AO 'G Salvini'   (Italy)

Author keywords

Bradykinin; Heart failure; LCZ696 (sacubitril valsartan); Natriuretic peptides; Neprilysin; Neuroendocrine syndrome

Indexed keywords

ANGIOTENSIN RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ATRIAL NATRIURETIC FACTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BINDING PROTEIN; BRAIN NATRIURETIC PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MEMBRANE METALLOENDOPEPTIDASE; MINERALOCORTICOID ANTAGONIST; NATRIURETIC FACTOR; NATRIURETIC PEPTIDE TYPE C; SACUBITRIL PLUS VALSARTAN; VASOPEPTIDASE INHIBITOR; CARDIOTONIC AGENT;

ADRENERGIC SYSTEM; HEART FAILURE; HUMAN; MOLECULAR BIOLOGY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; ANIMAL; PHYSIOLOGY;

ANIMALS; CARDIOTONIC AGENTS; HEART FAILURE; HUMANS; NATRIURETIC PEPTIDES;

EID: 84951952707     PISSN: 01435221     EISSN: 14708736     Source Type: Journal    
DOI: 10.1042/CS20150469     Document Type: Review

References (223)

1. Francis, G.S., Benedict, C., Johnstone, D.E., Kirlin, P.C., Nicklas, J., Liang, C.S., Kubo, S.H., Rudin-Toretsky, E. and Yusuf, S. (1990) Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 82, 1724-1729
2. Francis, G.S., McDonald, K.M. and Cohn, J.N. (1993) Neurohormonal activation in preclinical heart failure: remodeling and the potential for intervention. Circulation 87 Suppl. IV, IV-90-96
3. Benedict, C.R., Shelton, B., Johnstone, D.E., Francis, G., Greenberg, B., Konstam, M., Probstfield, J.L. and Yusuf, S. (1996) Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction. Circulation 94, 690-697
4. Volpe, M., Tritto, C., De Luca, N., Mele, A.F., Lembo, G., Rubattu, S., Romano, M., De Campora, P., Enea, I., Ricciardelli, B. et al. (1991) Failure of atrial natriuretic factor to increase with saline load in patients with dilated cardiomyopathy and mild heart failure. J. Clin. Invest. 88, 1481-1489
5. Magri, P., Rao, M.A., Cangianiello, S., Bellizzi, V., Russo, R., Mele, A.F., Andreucci, M., Memoli, B., De Nicola, L. and Volpe, M. (1998) Early impairment of renal hemodynamic reserve in patients with asymptomatic heart failure is restored by angiotensin II antagonism. Circulation 98, 2849-2854
6. Mastromarino, V., Volpe, M., Musumeci, M.B., Autore, C. and Conti, E. (2011) Erythropoietin and the heart: facts and perspectives. Clin. Sci. 120, 51-63
7. Sharpe, D.N., Murphy, J., Coxon, R. and Hannan, S.F. (1984) Enalapril in patients with chronic heart failure: a placebo-controlled, randomized, double-blind study. Circulation 70, 271-278
8. Captopril-Digoxin Multicenter Research Group (1988) Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure. JAMA 259, 539-544
9. Captopril Multicenter Research Group (1983) A placebo-controlled trial of captopril in refractory chronic congestive heart failure. J. Am. Coll. Cardiol. 2, 755-763
10. Le Jemtel, T.H., Keung, E., Frishman, W.H. and Ribner, H.S. (1982) Hemodynamic effects of captopril in patients with severe heart failure. Am. J. Cardiol. 49, 1484-1488
11. SOLVD Investigators (1991) Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N. Engl. J. Med. 325, 293-302
12. Jong, P. and Yusuf, S. (2002), Extended follow-up of the Studies of Left Ventricular Dysfunction (SOLVD) prevention and treatment trials. European Society of Cardiology Meeting, Berlin, Germany, 31 August-4 September 2002
13. Cohn, J.N. and Tognoni, G. (2001) A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N. Engl. J. Med. 345, 1667-1675
14. Pfeffer, M.A., Swedberg, K., Granger, C.B., Held, P., McMurray, J.J., Michelson, E.L., Olofsson, B., Ostergren, J., Yusuf, S. and Pocock, S. (2003) Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 362, 759-766
15. McMurray, J.J., Ostergren, J., Swedberg, K., Granger, C.B., Held, P., Michelson, E.L., Olofsson, B., Yusuf, S. and Pfeffer, M.A. (2003) Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 362, 767-771
16. Yusuf, S., Pfeffer, M.A., Swedberg, K., Granger, C.B., Held, P., McMurray, J.J., Michelson, E.L., Olofsson, B. and Ostergren, J. (2003) Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 362, 777-781
17. Pitt, B., Zannad, F., Remme, W.J., Cody, R., Castaigne, A., Perez, A., Palensky, J. and Wittes, J. (1999) Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N. Engl. J. Med. 341, 709-717
18. Pitt, B., Remme, W., Zannad, F.J., Neaton, J., Martinez, F., Roniker, B., Bittman, R., Hurley, S., Kleiman, J. and Gatlin, M. (2003) Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 348, 1309-1321
19. Zannad, F., McMurray, J.J., Drexler, H., Krum, H., van Veldhuisen, D.J., Swedberg, K., Shi, H., Vincent, J. and Pitt, B. (2010) Rationale and design of the Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure (EMPHASIS-HF). Eur. J. Heart Fail. 12, 617-622
20. Zannad, F., McMurray, J.J., Krum, H., van Veldhuisen, D.J., Swedberg, K., Shi, H., Vincent, J., Pocock, S.J. and Pitt, B. (2011) Eplerenone in patients with systolic heart failure and mild symptoms. N. Engl. J. Med. 364, 11-21
21. Hjalmarson, A., Goldstein, S., Fagerberg, B., Wedel, H., Waagstein, F., Kjekshus, J., Wikstrand, J., El Allaf, D., Vítovec, J., Aldershvile, J. et al. (2000) Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). MERIT-HF Study Group. JAMA 283, 1295-1302
22. CIBIS II Investigators and Committees (1999) The Cardiac Insufficiency Bisoprolol Study II (CIBIS II): a randomised trial. Lancet 353, 9-13
23. Packer, M., Bristow, M.R., Cohn, J.N., Colucci, W.S., Fowler, M.B., Gilbert, E.M. and Shusterman, N.H. (1996) The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N. Engl. J. Med. 334, 1349-1355
24. Packer, M., Coats, A.J., Fowler, M.B., Katus, H.A., Krum, H., Mohacsi, P., Rouleau, J.L., Tendera, M., Castaigne, A., Roecker, E.B. et al. (2001) Effect of carvedilol on survival in severe chronic heart failure. N. Engl. J. Med. 344, 1651-1658
25. Flather, M.D., Yusuf, S., Køber, L., Pfeffer, M., Hall, A., Murray, G., Torp-Pedersen, C., Ball, S., Pogue, J., Moyé, L. et al. (2000) Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 355, 1575-1581
26. McMurray, J.J., Adamopoulos, S., Anker, S.D., Auricchio, A., Böhm, M., Dickstein, K., Falk, V., Filippatos, G., Fonseca, C., Gomez-Sanchez, M.A. et al. (2012) ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur. J. Heart Fail. 14, 803-869
27. Haldeman, G.A., Croft, J.B., Giles, W.H. and Rashidee, A. (1999) Hospitalisation of patients with heart failure: National Hospital Discharge Survey, 1985 to 1995. Am. Heart J. 137, 352-360
28. Jaagosild, P., Dawson, N. and Thomas, C. (1998) Outcomes of acute exacerbation of severe congestive heart failure. Arch. Int. Med. 158, 1081-1089
29. Go, A.S., Mozaffarian, D., Roger, V.L., Benjamin, E.J., Berry, J.D., Borden, W.B., Bravata, D.M., Dai, S., Ford, E.S., Fox, C.S. et al. (2013) Heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation 127, e6-245
30. Braunwald, E. (2013) Heart failure. JACC Heart Fail 1, 1-20
31. Volpe, M., Rubattu, S. and Burnett, Jr, J. (2014) Natriuretic peptides in cardiovascular diseases: current use and perspectives. Eur. Heart J. 35, 419-425
32. McMurray, J.J., Pfeffer, M.A., Swedberg, K. and Dzau, V.J. (2004) Which inhibitor of the renin-angiotensin system should be used in chronic heart failure and acute myocardial infarction? Circulation 110, 3281-3288
33. Pitt, B., Chang, P. and Timmermans, P.B. (1995) Angiotensin II receptor antagonists in heart failure: rationale and design of the evaluation of losartan in the elderly (ELITE) trial. Cardiovasc. Drugs Ther. 9, 693-700
34. Witherow, F.N., Helmy, A., Webb, D.J., Fox, K.A. and Newby, D.E. (2001) Bradykinin contributes to the vasodilator effects of chronic angiotensin-converting enzyme inhibition in patients with heart failure. Circulation 104, 2177-2181
35. Witherow, F.N., Dawson, P., Ludlam, C.A., Fox, K.A. and Newby, D.E. (2002) Marked bradykinin-induced tissue plasminogen activator release in patients with heart failure maintained on long-term angiotensin-converting enzyme inhibitor therapy. J. Am. Coll. Cardiol. 40, 961-966
36. de Bold, A.J., Borenstein, H.B., Veress, A.T. and Sonnenberg, H. (1981) A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci 28, 89-94
37. Misono, K.S., Grammer, R.T., Fukumi, H. and Inagami, T. (1984) Rat atrial natriuretic factor: isolation, structure and biological activities of four major peptides. Biochem. Biophys. Res. Commun. 123, 444-451
38. Flynn, T.G., de Bold, M.L. and de Bold, A.J. (1983) The amino acid sequence of an atrial peptide with potent diuretic and natriuretic properties. Biochem. Biophys. Res. Commun. 117, 859-865
39. Currie, M.G., Geller, D.M., Cole, B.R., Siegel, N.R., Fok, K.F., Adams, S.P., Eubanks, S.R., Galluppi, G.R. and Needleman, P. (1984) Purification and sequence analysis of bioactive atrial peptides (atriopeptins). Science 223, 67-69
40. Kangawa, K., Tawaragi, Y., Oikawa, S., Mizuno, A., Sakuragawa, Y., Nakazato, H., Fukuda, A., Minamino, N. and Matsuo, H. (1984) Identification of rat γ atrial natriuretic polypeptide and characterization of the cDNA encoding its precursor. Nature 312, 152-155
41. Sudoh, T., Kangawa, K., Minamino, N. and Matsuo, H. (1988) A new natriuretic peptide in porcine brain. Nature 332, 78-81
42. Sudoh, T., Minamino, N., Kangawa, K. and Matsuo, H. (1990) C-type natriuretic peptide (CNP): a new member of natriuretic peptide family identified in porcine brain. Biochem. Biophys. Res. Commun. 168, 863-870
43. Yan, W., Wu, F., Morser, J. and Wu, Q. (2000) Corin, a transmembrane cardiac serine protease, acts as a pro-atrial natriuretic peptide-converting enzyme. Proc. Natl. Acad. Sci. U.S.A. 97, 8525-8529
44. Forssmann, W.G., Richter, R. and Meyer, M. (1998) The endocrine heart and natriuretic peptides: histochemistry, cell biology, and functional aspects of the renal urodilatin system. Histochem. Cell. Biol. 110, 335-357
45. de Bold, A.J., de Bold, M.L. and Sarda, I.R. (1986) Functional-morphological studies on in vitro cardionatrin release. J. Hypertens. Suppl. 4, S3-S7
46. Edwards, B.S., Zimmerman, R.S., Schwab, T.R., Heublein, D.M. and Burnett, Jr, J.C. (1988) Atrial stretch, not pressure, is the principal determinant controlling the acute release of atrial natriuretic factor. Circ. Res. 62, 191-195
47. Stasch, J.P., Hirth-Dietrich, C., Kazda, S. and Neuser, D. (1989) Endothelin stimulates release of atrial natriuretic peptides in vitro and in vivo. Life Sci. 45, 869-875
48. Soualmia, H., Barthelemy, C., Masson, F., Maistre, G., Eurin, J. and Carayon, A. (1997) Angiotensin II-induced phosphoinositide production and atrial natriuretic peptide release in rat atrial tissue. J. Cardiovasc. Pharmacol. 29, 605-611
49. Lachance, D., Garcia, R., Gutkowska, J., Cantin, M. and Thibault, G. (1986) Mechanisms of release of atrial natriuretic factor. I. Effect of several agonists and steroids on its release by atrial minces. Biochem. Biophys. Res. Commun. 135, 1090-1098
50. Thibault, G., Amiri, F. and Garcia, R. (1999) Regulation of natriuretic peptide secretion by the heart. Annu. Rev. Physiol. 61, 193-217
51. Cody, R.J., Atlas, S.A., Laragh, J.H., Kubo, S.H., Covit, A.B., Ryman, K.S., Shaknovich, A., Pondolfino, K., Clark, M., Camargo, M.J. et al. (1986) Atrial natriuretic factor in normal subjects and heart failure patients. Plasma levels and renal, hormonal, and hemodynamic responses to peptide infusion. J. Clin. Invest. 78, 1362-1374
52. Mukoyama, M., Nakao, K., Hosoda, K., Suga, S., Saito, Y., Ogawa, Y., Shirakami, G., Jougasaki, M., Obata, K., Yasue, H. et al. (1991) Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J. Clin. Invest. 87, 1402-1412
53. Abassia, Z., Karramb, T., Ellahamc, S., Winaver, J. and Hoffman, A. (2004) Implications of the natriuretic peptide system in the pathogenesis of heart failure: diagnostic and therapeutic importance. Pharmacol Therap. 102, 223-241
54. Lerman, A., Gibbons, R.J., Rodeheffer, R.J., Bailey, K.R., McKinley, L.J., Heublein, D.M. and Burnett, Jr, J.C. (1993) Circulating N-terminal atrial natriuretic peptide as a marker for symptomless left-ventricular dysfunction. Lancet 341, 1105-1109
55. Seilhamer, J.J., Arfsten, A., Miller, J.A., Lundquist, P., Scarborough, R.M., Lewicki, J.A. and Porter, J.G. (1989) Human and canine gene homologs of porcine brain natriuretic peptide. Biochem. Biophys. Res. Commun. 165, 650-658
56. Yandle, T.G. and Richards, A.M. (2015) B-type natriuretic peptide circulating forms: analytical and bioactivity issues. Clin. Chim. Acta 448, 195-205
57. Grepin, C., Dagnino, L., Robitaille, L., Haberstroh, L., Antakly, T. and Nemer, M. (1994) A hormone-encoding gene identifies a pathway for cardiac but not skeletal muscle gene transcription. Mol. Cell. Biol. 14, 3115-3129
58. Hagiwara, H., Sakaguchi, H., Itakura, M., Yoshimoto, T., Furuya, M., Tanaka, S. and Hirose, S. (1994) Autocrine regulation of rat chondrocyte proliferation by natriuretic peptide C and its receptor, natriuretic peptide receptor-B. J. Biol. Chem. 269, 10729-10733
59. Hagiwara, H., Sakaguchi, H., Lodhi, K.M., Suda, K. and Hirose, S. (1994) Subtype switching of natriuretic peptide receptors in rat chondrocytes during in vitro culture. J. Biochem. 116, 606-609
60. Suga, S., Nakao, K., Itoh, H., Komatsu, Y., Ogawa, Y., Hama, N. and Imura, H. (1992) Endothelial production of C-type natriuretic peptide and its marked augmentation by transforming growth factor-β. Possible existence of "vascular natriuretic peptide system. J. Clin. Invest. 90, 1145-1149
61. Wu, C., Wu, F., Pan, J., Morser, J. and Wu, Q. (2003) Furin-mediated processing of Pro-C-type natriuretic peptide. J. Biol. Chem. 278, 25847-25852
62. Yeung, V.T., Ho, S.K., Nicholls, M.G. and Cockram, C.S. (1996) Binding of CNP-22 and CNP-53 to cultured mouse astrocytes and effects on cyclic GMP. Peptides 17, 101-106
63. Totsune, K., Takahashi, K., Ohneda, M., Itoi, K., Murakami, O. and Mouri, T. (1994) C-type natriuretic peptide in the human central nervous system: distribution and molecular form. Peptides 15, 37-40
64. Stingo, A.J., Clavell, A.L., Heublein, D.M., Wei, C.M., Pittelkow, M.R. and Burnett, Jr, J.C. (1992) Presence of C-type natriuretic peptide in cultured human endothelial cells and plasma. Am. J. Physiol. 263, H1318-H1321
65. Minamino, N., Makino, Y., Tateyama, H., Kangawa, K and Matsuo, H. (1991) Characterization of immunoreactive human C-type natriuretic peptide in brain and heart. Biochem. Biophys. Res. Commun. 179, 535-542
66. Togashi, K., Kameya, T., Kurosawa, T., Hasegawa, N. and Kawakami, M. (1992) Concentrations and molecular forms of C-type natriuretic peptide in brain and cerebrospinal fluid. Clin. Chem. 38, 2136-2139
67. Wei, C.M., Heublein, D.M., Perrella, M.A., Lerman, A., Rodeheffer, R.J., McGregor, C.G., Edwards, W.D., Schaff, H.V. and Burnett, Jr, J.C. (1993) Natriuretic peptide system in human heart failure. Circulation 88, 1004-1009
68. Potter, L.R. (2005) Domain analysis of human transmembrane guanylyl cyclase receptors: implications for regulation. Front. Biosci. 10, 1205-1220
69. Chang, M.S., Lowe, D.G., Lewis, M., Hellmiss, R., Chen, E. and Goeddel, D.V. (1989) Differential activation by atrial and brain natriuretic peptides of two different receptor guanylate cyclases. Nature 341, 68-72
70. Abbey, S.E. and Potter, L.R. (2002) Vasopressin-dependent inhibition of the C-type natriuretic peptide receptor, NPR-B/GC-B, requires elevated intracellular calcium concentrations. J. Biol. Chem. 277, 42423-42430
71. Porter, J.G., Arfsten, A., Fuller, F., Miller, J.A., Gregory, L.C. and Lewicki, J.A. (1990) Isolation and functional expression of the human atrial natriuretic peptide clearance receptor cDNA. Biochem. Biophys. Res. Commun. 171, 796-803
72. Wilcox, J.N., Augustine, A., Goeddel, D.V. and Lowe, D.G. (1991) Differential regional expression of three natriuretic peptide receptor genes within primate tissues. Mol. Cell. Biol. 11, 3454-3462
73. Ashman, D.F., Lipton, R., Melicow, M.M. and Price, T.D. (1963) Isolation of adenosine 3', 5'-monophosphate and guanosine 3', 5'-monophosphate from rat urine. Biochem. Biophys. Res. Commun. 11, 330-334
74. Lohmann, S.M., Vaandrager, A.B., Smolenski, A., Walter, U. and De Jonge, H.R. (1997) Distinct and specific functions of cGMP-dependent protein kinases. Trends. Biochem. Sci. 22, 307-312
75. Kaupp, U.B. and Seifert, R. (2002) Cyclic nucleotide-gated ion channels. Physiol. Rev. 82, 769-824
76. Sosa, R.E., Volpe, M., Marion, D.N., Atlas, S.A., Laragh, J.H., Vaughan, Jr, E.D. and Maack, T. (1986) Relationship between renal hemodynamic and natriuretic effects of atrial natriuretic factor. Am. J. Physiol. 250 3 Pt 2, F520-F524
77. Kishimoto, I., Dubois, S.K. and Garbers, D.L. (1996) The heart communicates with the kidney exclusively through the guanylyl cyclase-A receptor: acute handling of sodium and water in response to volume expansion. Proc. Natl. Acad. Sci. U.S.A. 93, 6215-6219
78. Marin-Grez, M., Fleming, J.T. and Steinhausen, M. (1986) Atrial natriuretic peptide causes pre-glomerular vasodilatation and post-glomerular vasoconstriction in rat kidney. Nature 324, 473-476
79. Harris, P.J., Thomas, D. and Morgan, T.O. (1987) Atrial natriuretic peptide inhibits angiotensin-stimulated proximal tubular sodium and water reabsorption. Nature 326, 697-698
80. Light, D.B., Corbin, J.D. and Stanton, B.A. (1990) Dual ion-channel regulation by cyclic GMP and cyclic GMP-dependent protein kinase. Nature 344, 336-339
81. Chabrier, P.E., Roubert, P., Lonchampt, M.O., Plas, P. and Braquet, P. (1988) Regulation of atrial natriuretic factor receptors by angiotensin II in rat vascular smooth muscle cells. J. Biol. Chem. 263, 13199-202
82. Gopi, V., Parthasarathy, A., Umadevi, S. and Vellaichamy, E. (2013) Angiotensin-II down-regulates cardiac natriuretic peptide receptor-A mediated anti-hypertrophic signaling in experimental rat hearts. Indian J. Exp. Biol. 51, 48-55
83. Yoshimoto, T., Naruse, M., Naruse, K., Shionoya, K., Tanaka, M., Tanabe, A., Hagiwara, H., Hirose, S., Muraki, T. and Demura, H. (1996) Angiotensin II-dependent down-regulation of vascular natriuretic peptide type C receptor gene expression in hypertensive rats. Endocrinology 13, 1102-1107
84. Suga, S., Itoh, H., Komatsu, Y., Ogawa, Y., Hama, N., Yoshimasa, T. and Nakao, K. (1993) Cytokine-induced C-type natriuretic peptide (CNP) secretion from vascular endothelial cells-evidence for CNP as a novel autocrine/paracrine regulator from endothelial cells. Endocrinology 133, 3038-3041
85. Drewett, J.G., Fendly, B.M., Garbers, D.L. and Lowe, D.G. (1995) Natriuretic peptide receptor-B (guanylyl cyclase-B) mediates C-type natriuretic peptide relaxation of precontracted rat aorta. J. Biol. Chem. 270, 4668-4674
86. Furuya, M., Yoshida, M., Hayashi, Y., Ohnuma, N., Minamino, N., Kangawa, K. and Matsuo, H. (1991) C-type natriuretic peptide is a growth inhibitor of rat vascular smooth muscle cells. Biochem. Biophys. Res. Commun. 177, 927-931
87. Kohno, M., Yokokawa, K., Yasunari, K., Kano, H., Minami, M., Ueda, M. and Yoshikawa, J. (1997) Effect of natriuretic peptide family on the oxidized LDL-induced migration of human coronary artery smooth muscle cells. Circ. Res. 81, 585-590
88. Barton, M., Beny, J.L., d'Uscio, L.V., Wyss, T., Noll, G. and Lüscher, T.F. (1998) Endothelium-independent relaxation and hyperpolarization to C-type natriuretic peptide in porcine coronary arteries. J. Cardiovasc. Pharmacol. 31, 377-383
89. Burnett Jr, J.C., Granger, J.P. and Opgenorth, T.J. (1984) Effects of synthetic atrial natriuretic factor on renal function and renin release. Am. J. Physiol. 247, F863-F866
90. Volpe, M., Odell, G., Kleinert, H.D., Müller, F., Camargo, M.J., Laragh, J.H., Maack, T., Vaughan, Jr, E.D. and Atlas, S.A. (1985) Effect of atrial natriuretic factor on blood pressure, renin, and aldosterone in Goldblatt hypertension. Hypertension 7 3 Pt 2, I43-I48
91. Lean, A., Racz, K., Gutkowska, J., Nguyen, T.T., Cantin, M. and Genest, J. (1984) Specific receptor-mediated inhibition by synthetic atrial natriuretic factor of hormone-stimulated steroidogenesis in cultured bovine adrenal cells. Endocrinology 115, 1636-1638
92. Chartier, L., Schiffrin, E., Thibault, G. and Garcia, R. (1984) Atrial natriuretic factor inhibits the stimulation of aldosterone secretion by angiotensin II, ACTH and potassium in vitro and angiotensin II-induced steroidogenesis in vivo. Endocrinology 115, 2026-2028
93. Volpe, M., Cuocolo, A., Vecchione, F., Mele, A.F., Condorelli, M. and Trimarco, B. (1987) Vagal mediation of the effects of atrial natriuretic factor on blood pressure and arterial baroreflexes in the rabbit. Circ Res. 60, 747-55
94. Volpe, M., Luca, N., Bigazzi, M.C., Vecchione, F., Lembo, G., Condorelli, M. and Trimarco, B. (1988) Atrial natriuretic factor potentiates forearm reflex vasoconstriction induced by cardiopulmonary receptor deactivation in man. Circulation 77, 849-55
95. Volpe, M., Lembo, G., Condorelli, G., Luca, N., Lamenza, F., Indolfi, C. and Trimarco, B. (1990) Converting enzyme inhibition prevents the effects of atrial natriuretic factor on baroreflex responses in humans. Circulation 82, 1214-1221
96. Franco, F., Dubois, S.K., Peshock, R.M. and Shohet, R.V. (1998) Magnetic resonance imaging accurately estimates LV mass in a transgenic mouse model of cardiac hypertrophy. Am. J. Physiol. 274, H679-H683
97. Barbee, R.W., Perry, B.D., Re, R.N., Murgo, J.P. and Field, L.J. (1994) Hemodynamics in transgenic mice with overexpression of atrial natriuretic factor. Circ. Res. 74, 747-751
98. Knowles, J.W., Esposito, G., Mao, L., Hagaman, J.R., Fox, J.E., Smithies, O., Rockman, H.A. and Maeda, N. (2001) Pressure-independent enhancement of cardiac hypertrophy in natriuretic peptide receptor A-deficient mice. J. Clin. Invest. 107, 975-984
99. Kishimoto, I., Rossi, K. and Garbers, D.L. (2001) A genetic model provides evidence that the receptor for atrial natriuretic peptide (guanylyl cyclase-A) inhibits cardiac ventricular myocyte hypertrophy. Proc. Natl. Acad. Sci. U.S.A. 98, 2703-2706
100. Hayashi, D., Kudoh, S., Shiojima, I., Zou, Y., Harada, K., Shimoyama, M., Imai, Y., Monzen, K., Yamazaki, T., Yazaki, Y. et al. (2004) Atrial natriuretic peptide inhibits cardiomyocyte hypertrophy through mitogen-activated protein kinase phosphatase-1. Biochem. Biophys. Res. Commun. 322, 310-319
101. Fujita, S., Shimojo, N., Terasaki, F., Otsuka, K., Hosotani, N., Kohda, Y., Tanaka, T., Nishioka, T., Yoshida, T., Hiroe, M. et al. (2013) Atrial natriuretic peptide exerts protective action against angiotensin II-induced cardiac remodeling by attenuating inflammation via endothelin-1/endothelin receptor A cascade. Heart Vessels 28, 646-657
102. Calderone, A., Thaik, C.M., Takahashi, N., Chang, D.L. and Colucci, W.S. (1998) Nitric oxide, atrial natriuretic peptide, and cyclic GMP inhibit the growth-promoting effects of norepinephrine in cardiac myocytes and fibroblasts. J. Clin. Invest. 101, 812-818
103. Rubattu, S., Bigatti, G., Evangelista, A., Lanzani, C., Stanzione, R., Zagato, L., Manunta, P., Marchitti, S., Venturelli, V. and Bianchi, G. (2006) Association of atrial natriuretic peptide and type a natriuretic peptide receptor gene polymorphisms with left ventricular mass in human essential hypertension. J. Am. Coll. Cardiol. 48, 499-505
104. Hamad, A.M., Clayton, A., Islam, B. and Knox, A.J. (2003) Guanylyl cyclases, nitric oxide, natriuretic peptides, and airway smooth muscle function. Am. J. Physiol. Lung Cell. Mol. Physiol. 285, L973-L983
105. Klinger, J.R., Petit, R.D., Curtin, L.A., Warburton, R.R., Wrenn, D.S., Steinhelper, M.E., Field, L.J. and Hill, N.S. (1993) Cardiopulmonary responses to chronic hypoxia in transgenic mice that overexpress ANP. J. Appl. Physiol. 75, 198-205
106. Klinger, J.R., Warburton, R.R., Pietras, L.A., Smithies, O., Swift, R. and Hill, N.S. (1999) Genetic disruption of atrial natriuretic peptide causes pulmonary hypertension in normoxic and hypoxic mice. Am. J. Physiol. 276, L868-L874
107. Itoh, T., Nagaya, N., Murakami, S., Fujii, T., Iwase, T., Ishibashi-Ueda, H., Yutani, C., Yamagishi, M., Kimura, H. and Kangawa, K. (2004) C-type natriuretic peptide ameliorates monocrotaline-induced pulmonary hypertension in rats. Am. J. Respir. Crit. Care Med. 170, 1204-1211
108. Murakami, S., Nagaya, N., Itoh, T., Fujii, T., Iwase, T., Hamada, K., Kimura, H. and Kangawa, K. (2004) C-type natriuretic peptide attenuates bleomycin-induced pulmonary fibrosis in mice. Am. J. Physiol. Lung Cell. Mol. Physiol. 287, L1172-L1177
109. Sengenes, C., Berlan, M., Glisezinski, I., Lafontan, M. and Galitzky, J. (2000) Natriuretic peptides: a new lipolytic pathway in human adipocytes. FASEB J. 14, 1345-1351
110. Sengenes, C., Zakaroff-Girard, A., Moulin, A., Berlan, M., Bouloumié, A., Lafontan, M. and Galitzky, J. (2002) Natriuretic peptide-dependent lipolysis in fat cells is a primate specificity. Am. J. Physiol. Regul. Integr. Comp. Physiol. 283, R257-R265
111. Sengenes, C., Bouloumie, A., Hauner, H., Berlan, M., Busse, R., Lafontan, M. and Galitzky, J. (2003) Involvement of a cGMP-dependent pathway in the natriuretic peptide-mediated hormone-sensitive lipase phosphorylation in human adipocytes. J. Biol. Chem. 278, 48617-48626
112. Charles, C.J., Espiner, E.A., Nicholls, M.G., Richards, A.M., Yandle, T.G., Protter, A. and Kosoglou, T. (1996) Clearance receptors and endopeptidase 24.11: equal role in natriuretic peptide metabolism in conscious sheep. Am. J. Physiol. 271, R373-R380
113. Ruskoaho, H. (1992) Atrial natriuretic peptide: synthesis, release, and metabolism. Pharmacol. Rev. 44, 479-602
114. Nakao, K., Sugawara, A., Morii, N., Sakamoto, M., Yamada, T., Itoh, H., Shiono, S, Saito, Y., Nishimura, K., Ban, T. et al. (1986) The pharmacokinetics of alpha-human atrial natriuretic polypeptide in healthy subjects. Eur. J. Clin. Pharmacol. 31, 101-103
115. Yandle, T.G., Richards, A.M., Nicholls, M.G., Cuneo, R., Espiner, E.A. and Livesey, J.H. (1986) Metabolic clearance rate and plasma half life of alpha-human atrial natriuretic peptide in man. Life Sci 38, 1827-1833
116. Crozier, I.G., Nicholls, M.G., Ikram, H., Espiner, E.A., Yandle, T.G. and Jans, S. (1986) Atrial natriuretic peptide in humans. Production and clearance by various tissues. Hypertension 8, II11-II15
117. Schutten, H.J., Henriksen, J.H. and Warberg, J. (1987) Organ extraction of atrial natriuretic peptide (ANP) in man. Significance of sampling site. Clin. Physiol. 7, 125-132
118. Hollister, A.S., Rodeheffer, R.J., White, F.J., Potts, J.R., Imada, T. and Inagami, T. (1989) Clearance of atrial natriuretic factor by lung, liver, and kidney in human subjects and the dog. J. Clin. Invest. 83, 623-628
119. Richards, A.M., Crozier, I.G., Yandle, T.G., Espiner, E.A., Ikram, H. and Nicholls, M.G. (1993) Brain natriuretic factor: regional plasma concentrations and correlations with haemodynamic state in cardiac disease. Br. Heart J. 69, 414-417
120. Maack, T., Suzuki, M., Almeida, F.A., Nussenzveig, D., Scarborough, R.M., McEnroe, G.A. and Lewicki, J.A. (1987) Physiological role of silent receptors of atrial natriuretic factor. Science 238, 675-678
121. Kerr, M.A. and Kenny, A.J. (1974) The purification and specificity of a neutral endopeptidase from rabbit kidney brush border. Biochem. J. 137, 477-488
122. Malfroy, B., Swerts, J.P., Guyon, A., Roques, B.P. and Schwartz, J.C. (1978) High-affinity enkephalin-degrading peptidase in brain is increased after morphine. Nature 276, 523-526
123. Sonnenberg, J.L., Sakane, Y., Jeng, A.Y., Koehn, J.A., Ansell, J.A., Wennogle, L.P. and Ghai, R.D. (1988) Identification of protease 3.4.24.11 as the major atrial natriuretic factor degrading enzyme in the rat kidney. Peptides 9, 173-180
124. Stephenson, S.L. and Kenny, A.J. (1987) The hydrolysis of alpha-human atrial natriuretic peptide by pig kidney microvillar membranes is initiated by endopeptidase-24.11. Biochem. J. 243, 183-187
125. Vanneste, Y., Michel, A., Dimaline, R., Najdovski, T. and Deschodt-Lanckman, M. (1988) Hydrolysis of alpha-human atrial natriuretic peptide in vitro by human kidney membranes and purified endopeptidase-24.11. Evidence for a novel cleavage site. Biochem. J. 254, 531-537
126. Watanabe, Y., Nakajima, K., Shimamori, Y. and Fujimoto, Y. (1997) Comparison of the hydrolysis of the three types of natriuretic peptides by human kidney neutral endopeptidase 24.11. Biochem. Mol. Med. 61, 47-51
127. Potter, L.R., Yoder, A.R., Flora, D.R., Antos, L.K. and Dickey, D.M. (2009) Natriuretic peptides: their structures, receptors, physiologic functions and therapeutic applications. Handb. Exp. Pharmacol. 191, 341-366
128. Kenny, A.J., Bourne, A. and Ingram, J. (1993) Hydrolysis of human and pig brain natriuretic peptides, urodilatin, C-type natriuretic peptide and some C-receptor ligands by endopeptidase-24.11. Biochem. J. 291 Pt 1, 83-88
129. Smith, M.W., Espiner, E.A., Yandle, T.G., Charles, C.J. and Richards, A.M. (2000) Delayed metabolism of human brain natriuretic peptide reflects resistance to neutral endopeptidase. J. Endocrinol. 167, 239-246
130. Dickey, D.M. and Potter, L.R. (2010) Human B-type natriuretic peptide is not degraded by meprin A. Biochem. Pharmacol. 80, 1007-1011
131. Duckworth, W.C., Bennett, R.G. and Hamel, F.G. (1998) Insulin degradation: progress and potential. Endocr. Rev. 19, 608-624
132. Muller, D., Baumeister, H., Buck, F. and Richter, D. (1991) Atrial natriuretic peptide (ANP) is a high-affinity substrate for rat insulin-degrading enzyme. Eur. J. Biochem. 202, 285-292
133. Muller, D., Schulze, C., Baumeister, H., Buck, F. and Richter, D. (1992) Rat insulin-degrading enzyme: cleavage pattern of the natriuretic peptide hormones ANP, BNP, and CNP revealed by HPLC and mass spectrometry. Biochemistry 31, 11138-11143
134. Charles, C.J., Espiner, E.A., Nicholls, M.G., Richards, A.M., Yandle, T.G., Protter, A. and Kosoglou, T. (1996) Clearance receptors and endopeptidase 24.11: equal role in natriuretic peptide metabolism in conscious sheep. Am. J. Physiol. 271, R373-R380
135. Koepke, J.P., Tyler, L.D., Trapani, A.J., Bovy, P.R., Spear, K.L., Olins, G.M. and Blaine, E.H. (1989) Interaction of non-guanylatecyclase-linked atriopeptin receptor ligand and endopeptidase inhibitor in conscious rats. J. Pharmacol. Exp. Ther. 249, 172-176
136. Kukkonen, P., Vuolteenaho, O. and Ruskoaho, H. (1992) Basal and volume expansion-stimulated plasma atrial natriuretic peptide concentrations and hemodynamics in conscious rats: effects of SCH 39.370, an endopeptidase inhibitor, and C-ANF-(4-23), a clearance receptor ligand. Endocrinology 130, 755-765
137. Okolicany, J., McEnroe, G.A., Koh, G.Y., Lewicki, J.A. and Maack, T. (1992) Clearance receptor and neutral endopeptidase-mediated metabolism of atrial natriuretic factor. Am. J. Physiol. 263, F546-F553
138. Hashimoto, Y., Nakao, K., Hama, N., Imura, H., Mori, S., Yamaguchi, M., Yasuhara, M. and Hori, R. (1994) Clearance mechanisms of atrial and brain natriuretic peptides in rats. Pharm. Res. 11, 60-64
139. Shenker, Y., Sider, R.S., Ostafin, E.A. and Grekin, R.J. (1985) Plasma levels of immunoreactive atrial natriuretic factor in healthy subjects and in patients with edema. J. Clin. Invest. 76, 1684-1687
140. Volpe, M., Mele, A.F., Luca, N., Golino, P., Bondiolotti, G., Camargo, M.J., Atlas, S.A. and Trimarco, B. (1986) Carotid baroreceptor unloading decreases plasma atrial natriuretic factor in hypertensive patients. J. Hypertens. Suppl. 4, S519-S522
141. Trimarco, B., Lembo, G., De Luca, N., Volpe, M., Ricciardelli, B., Condorelli, G., Rosiello, G. and Condorelli, M. (1989) Blunted sympathetic response to cardiopulmonary receptor unloading in hypertensive patients with left ventricular hypertrophy. A possible compensatory role of atrial natriuretic factor. Circulation 80, 883-892
142. Volpe, M., Tritto, C., DeLuca, N., Rubattu, S., Mele, A.F., Lembo, G., Enea, I., deCampora, P., Rendina, V. and Romano, M. (1992) Angiotensin converting enzyme inhibition restores cardiac and hormonal responses to volume overload in patients with dilated cardiomyopathy and mild heart failure. Circulation 86, 1800-1809
143. Raine, A.E., Erne, P., Burgisser, E., Müller, F.B., Bolli, P., Burkart, F. and Bühler, FR. (1986) Atrial natriuretic peptide and atrial pressure in patients with congestive heart failure. N. Engl. J. Med. 315, 533-537
144. Hensen, J., Abraham, W.T., Lesnefsky, E.J., Levenson, B., Groves, B.M., Schröder, K., Schrier, R.W. and Dürr, J. (1992) Atrial natriuretic peptide kinetic studies in patients with cardiac dysfunction. Kidney Int. 41, 1333-1339
145. Focaccio, A., Volpe, M., Ambrosio, G., Lembo, G., Pannain, S., Rubattu, S., Enea, I., Pignalosa, S. and Chiariello, M. (1993) Angiotensin II directly stimulates release of atrial natriuretic factor in isolated rabbit hearts. Circulation 87, 192-198
146. Bae, E.H., Ma, S.K., Lee, J. and Kim, S.W. (2011) Altered regulation of renal nitric oxide and atrial natriuretic peptide systems in angiotensin II-induced hypertension. Regul. Pept. 170, 31-37
147. Hirsch, A.T., Creager, M.A. and Dzau, V.J. (1989) Relation of atrial natriuretic factor to vasoconstrictor hormones and regional blood flow in congestive heart failure. Am. J. Cardiol. 63, 211-216
148. Kanamori, T., Wada, A., Tsutamoto, T. and Kinoshita, M. (1995) Possible regulation of renin release by ANP in dogs with heart failure. Am. J. Physiol. 268, H2281-H2287
149. Moe, G.W., Forster, C., de Bold, A.J. and Armstrong, P.W. (1990) Pharmacokinetics, hemodynamic, renal, and neurohormonal effects of atrial natriuretic factor in experimental heart failure. Clin. Invest. Med. 13, 111-118
150. Cody, R.J., Atlas, S.A., Laragh, J.H., Kubo, S.H., Covit, A.B., Ryman, K.S., Shaknovich, A., Pondolfino, K., Clark, M., Camargo, M.J. et al. (1986) Plasma levels and renal, hormonal, and hemodynamic responses to peptide infusion. J. Clin. Invest. 78, 1362-1374
151. Volpe, M., Mele, A.F., Indolfi, C., De Luca, N., De Luca, N., Lembo, G., Focaccio, A., Condorelli, M. and Trimarco, B. (1987) Hemodynamic and hormonal effects of atrial natriuretic factor in patients with essential hypertension. J. Am. Coll. Cardiol. 10, 787-93
152. Lohmeier, T.E., Mizelle, H.L., Reinhart, G.A., Montani, J.P., Hord, Jr, C.E. and Didlake, R.H. (1996) Atrial natriuretic peptide and sodium homeostasis in compensated heart failure. Am. J. Physiol. 271, R1353-R1363
153. Costello-Boerrigter, L.C., Boerrigter, G. and Burnett, Jr, J.C. (2003) Revisiting salt and water retention: new diuretics, aquaretics, and natriuretics. Med. Clin. North. Am. 87, 475-491
154. Stevens, T.L., Burnett, Jr, J.C., Kinoshita, M., Matsuda, Y. and Redfield, M.M. (1995) A functional role for endogenous atrial natriuretic peptide in a canine model of early left ventricular dysfunction. J. Clin. Invest. 95, 1101-1108
155. Laragh, J.H. (1985) Atrial natriuretic hormone, the renin-aldosterone axis, and blood pressure-electrolyte homeostasis. N. Engl. J. Med. 313, 1330-1340
156. Harris, P.J., Thomas, D. and Morgan, T.O. (1987) Atrial natriuretic peptide inhibits angiotensin-stimulated proximal tubular sodium and water reabsorption. Nature 326, 697-698
157. Wada, A., Tsutamoto, T., Maeda, Y., Kanamori, T., Matsuda, Y. and Kinoshita, M. (1996) Endogenous atrial natriuretic peptide inhibits endothelin-1 secretion in dogs with severe congestive heart failure. Am. J. Physiol. 270, H1819-H1824
158. Charloux, A., Piquard, F., Doutreleau, S., Brandenberger, G. and Geny, B. (2003) Mechanisms of renal hyporesponsiveness to ANP in heart failure. Eur. J. Clin. Invest. 33, 769-778
159. Mangiafico, S., Costello-Boerrigter, L.C., Andersen, I.A., Cataliotti, A. and Burnett, Jr, J.C. (2013) Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics. Eur. Heart J. 34, 886-893
160. Fielitz, J., Dendorfer, A., Pregla, R., Ehler, E., Zurbrügg, H.R., Bartunek, J., Hetzer, R. and Regitz-Zagrosek, V. (2002) Neutral endopeptidase is activated in cardiomyocytes in human aortic valve stenosis and heart failure. Circulation 105, 286-289
161. McKie, P.M., Ichiki, T. and Burnett, Jr, J.C. (2012) M-atrial natriuretic peptide: a novel antihypertensive protein therapy. Curr. Hypertens. Rep. 14, 62-69
162. McKie, P.M., Cataliotti, A., Ichiki, T., Sangaralingham, S.J., Chen, H.H. and Burnett, Jr, J.C. (2013) M-atrial natriuretic peptide and nytroglycerin in a canine model of experimental acute hypertensive heart failure: a differential actions of 2 cGMP activating therapeutics. J. Am. Heart Ass. 3, e000206. doi: 10.1161/JAHA.113.000206
163. Colucci, W.S., Elkayam, U., Horton, D.P., Abraham, W.T., Bourge, R.C., Johnson, A.D., Wagoner, L.E., Givertz, M.M., Liang, C.S., Neibaur, M. et al. (2000) Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N. Engl. J. Med. 343, 246-253
164. Sackner-Bernstein, J.D., Kowalski, M., Fox, M. and Aaronson, K. (2005) Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA 293, 1900-1905
165. O'Connor, C.M., Starling, R.C., Hernandez, A.F., Armstrong, P.W., Dickstein, K., Hasselblad, V., Heizer, G.M., Komajda, M., Massie, B.M., McMurray, J.J. et al. (2011) Effect of nesiritide in patients with acute decompensated heart failure. N. Engl. J. Med. 365, 32-43
166. vonLueder, T.G., Sangaralingham, S.J., Wang, B.H., Kompa, A.R., Atar, D., Burnett, Jr, J.C. and Krum, H. (2013) Renin-angiotensin blockade combined with natriuretic peptide system augmentation: novel therapeutic concepts to combat heart failure. Circ. Heart Fail. 6, 594-605
167. Schweitz, H., Vigne, P., Moinier, D., Frelin, C. and Lazdunski, M. (1992) A new member of the natriuretic peptide family is present in the venom of the green mamba (Dendroaspisangusticeps). J. Biol. Chem. 267, 13928-13932
168. Dickey, D.M. and Potter, L.R. (2011) Dendroaspis natriuretic peptide and the designer natriuretic peptide, CD-NP, are resistant to proteolytic inactivation. J. Mol. Cell. Cardiol. 51, 67-71
169. Martin, F.L., Sangaralingham, S.J., Huntley, B.K., McKie, P.M., Ichiki, T., Chen, H.H., Korinek, J., Harders, G.E. and Burnett, Jr, J.C. (2012) CD-NP: a novel engineered dual guanylylcyclase activator with anti-fibrotic actions in the heart. PLoS One 7, e52422
170. Neutel, J., Rolston, W., Maddok, S., Goldsmith, S., Koren, M., Bill, V.A., Burnett, J. and Lieu, H.D. (2012) Initial experience with subcutaneous infusion of cenderitide in chronic heart failure patients. J. Am. Coll. Cardiol. 59, E1037
171. Hirsch, J.R., Meyer, M. and Forssmann, W.G. (2006) ANP and urodilatin: who is who in the kidney. Eur. J. Med. Res. 11, 447-454
172. Lee, C. and Burnett, Jr, J.C. (2007) Discovery of a novel synthetic natriuretic peptide, CU-PN. J. Card. Fail. 13 6 Suppl. 2, S74
173. Erdos, E.G. and Skidgel, R.A. (1989) Neutral endopeptidase 24.11 (enkephalinase) and related regulators of peptide hormones. FASEB J. 3, 145-151
174. Roques, B.P., Noble, F., Daugé, V., Fournié-Zaluski, M.C. and Beaumont, A. (1993) Neutral endopeptidase 24.11: structure, inhibition, and experimental and clinical pharmacology. Pharmacol. Rev. 45, 87-146
175. Yamamoto, K., Chappell, M.C., Brosnihan, K.B. and Ferrario, C.M. (1992) In vivo metabolism of angiotensin I by neutral endopeptidase (EC 3.4.24.11) in spontaneously hypertensive rats. Hypertension 19, 692-696
176. Richards, A.M., Wittert, G.A., Espiner, E.A., Yandle, T.G., Ikram, H. and Frampton, C. (1992) Effect of inhibition of endopeptidase 24.11 on responses to angiotensin II in human volunteers. Circ. Res. 71, 1501-1507
177. Iwata, N., Tsubuki, S., Takaki, Y., Shirotani, K., Lu, B., Gerard, N.P., Gerard, C., Hama, E., Lee, H.J. and Saido, T.C. (2001) Metabolic regulation of brain Aβ by neprilysin. Science 292, 1550-1552
178. Jeng, A.Y., Savage, P., Beil, M.E., Bruseo, C.W., Hoyer, D., Fink, C.A. and Trapani, A.J. (2002) CGS 34226, a thiol-based dual inhibitor of endothelin converting enzyme-1 and neutral endopeptidase 24.11. Clin. Sci. 103 suppl 1, 98S-101S
179. Campbell, D.J. (2003) Vasopeptidase inhibition. A double-edge sword? Hypertension 41, 383-389
180. Richards, A.M., Wittert, G.A., Crozier, I.G., Espiner, E.A., Yandle, T.G., Ikram, H. and Frampton, C. (1993) Chronic inhibition of endopeptidase 24.11 in essential hypertension: evidence for enhanced atrial natriuretic peptide and angiotensin II. J. Hypertens. 11, 407-416
181. Campbell, D.J., Anastasopoulos, F., Duncan, A.M., James, G.M., Kladis, A. and Briscoe, T.A. (1998) Effects of neutral endopeptidase inhibition and combined angiotensin converting enzyme and neutral endopeptidase inhibition on angiotensin and bradykinin peptides in rats. J. Pharmacol. Exp. Ther. 287, 567-577
182. Ura, N., Carretero, O.A. and Erdos, E.G. (1987) Role of renal endopeptidase 24.11 in kinin metabolism in vitro and in vivo. Kidney Int. 32, 507-513
183. Smits, G.J., McGraw, D.E. and Trapani, A.J. (1990) Interaction of ANP and bradykinin during endopeptidase 24.11 inhibition: renal effects. Am. J. Physiol. 258, F1417-F1424
184. Schriefer, J.A., Broudy, E.P. and Hassen, A.H. (1996) Endopeptidase inhibitors decrease myocardial ischemia/reperfusion injury in an in vivo rabbit model. J. Pharmacol. Exp. Ther. 278, 1034-1039
185. Yang, X.P., Liu, Y.H., Peterson, E. and Carretero, O.A. (1997) Effect of neutral endopeptidase 24.11 inhibition on myocardial ischemia/reperfusion injury: the role of kinins. J. Cardiovasc. Pharmacol. 29, 250-256
186. Piedimonte, G., Nadel, J.A., Long, C.S. and Hoffman, J.I.E. (1994) Neutral endopeptidase in the heart: Neutral endopeptidase inhibition prevents isoproterenol-induced myocardial hypoperfusion in rats by reducing bradykinin degradation. Circ. Res. 75, 770-779
187. Galli, A. and Lombardi, F. (2014) Neprilysin inhibition for heart failure. N. Engl. J. Med. 371, 2335
188. Northridge, D.B., Jardine, A.G., Alabaster, C.T., Barclay, P.L., Connell, J.M., Dargie, H.J., Dilly, S.G., Findlay, I.N., Lever, A.F. and Samuels, G.M. (1989) Effects of UK 69 578: a novel atriopeptidase inhibitor. Lancet 2, 591-593
189. Richards, M., Espiner, E., Frampton, C., Ikram, H., Yandle, T., Sopwith, M. and Cussans, N. (1990) Inhibition of endopeptidase EC 24.11 in humans: renal and endocrine effects. Hypertension 16, 269-276
190. Favrat, B., Burnier, M., Nussberger, J., Lecomte, J.M., Brouard, R., Waeber, B. and Brunner, H.R. (1995) Neutral endopeptidase versus angiotensin converting enzyme inhibition in essential hypertension. J. Hypertens. 13, 797-804
191. Ando, S., Rahman, M.A., Butler, G.C., Senn, B.L. and Floras, J.S. (1995) Comparison of candoxatril and atrial natriuretic factor in healthy men: effects on hemodynamics, sympathetic activity, heart rate variability, and endothelin. Hypertension 26, 1160-1166
192. Bevan, E.G., Connell, J.M., Doyle, J., Carmichael, H.A., Davies, D.L., Lorimer, A.R. and McInnes, G.T. (1992) Candoxatril, a neutral endopeptidase inhibitor: efficacy and tolerability in essential hypertension. J. Hypertens. 10, 607-613
193. Kentsch, M., Otter, W., Drummer, C., Nötges, A., Gerzer, R. and Müller-Esch, G. (1996) Neutral endopeptidase 24.11 inhibition may not exhibit beneficial haemodynamic effects in patients with congestive heart failure. Eur. J. Clin. Pharmacol. 51, 269-272
194. Nussberger, J., Cugno, M., Amstutz, C., Cicardi, M., Pellacani, A. and Agostoni, A. (1998) Plasma bradykinin in angio-oedema. Lancet 351, 1693-1697
195. Nussberger, J., Cugno, M. and Cicardi, M. (2002) Bradykinin-mediated angioedema. N. Engl. J. Med. 347, 621-622
196. O'Connor, C.M., Gattis, W.A., Gheorghiade, M., Granger, C.B., Gilbert, J., McKenney, J.M., Messineo, F.C., Burnett, J.C., Katz, S.D., Elkayam, U. et al. (1999) A randomized trial of ecadotril versus placebo in patients with mild to moderate heart failure: the US ecadotril pilot safety study. Am. Heart J. 138, 1140-1148
197. Cleland, J.G. and Swedberg, K. (1998) Lack of efficacy of neutral endopeptidase inhibitor ecadotril in heart failure. The International Ecadotril Multicentre Dose-Ranging Study Investigators. Lancet 351, 1657-1658
198. Fournié-Zaluski, M.C., Coric, P., Turcaud, S., Rousselet, N., Gonzalez, W., Barbe, B., Pham, I., Jullian, N., Michel, J.B. and Roques, B.P. (1994) New dual inhibitors of neutral endopeptidase and angiotensin-converting enzyme: rational design, bioavailability, and pharmacological responses in experimental hypertension. J. Med. Chem. 37, 1070-1083
199. Flynn, G.A., Beight, D.W., Mehdi, S., Koehl, J.R., Giroux, E.L., French, J.F., Hake, P.W. and Dage, R.C. (1993) Application of a conformationally restricted Phe-Leu dipeptide mimetic to the design of a combined inhibitor of angiotensin I-converting enzyme and neutral endopeptidase 24.11. J. Med. Chem. 36, 2420-2423
200. Kirk, J.E. and Wilkins, M.R. (1996) Renal effects of concurrent E-24.11 and ACE inhibition in the aorto-venocaval fistula rat. Br. J. Pharmacol. 119, 943-948
201. Packer, M., Califf, R.M., Konstam, M.A., Krum, H., McMurray, J.J., Rouleau, J.L. and Swedberg, K. (2002) Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation 106, 920-926
202. McClean, D.R., Ikram, H., Garlick, A.H., Richards, A.M., Nicholls, M.G. and Crozier, I.G. (2000) The clinical, cardiac, renal, arterial and neurohormonal effects of omapatrilat, a vasopeptidase inhibitor, in patients with chronic heart failure. J. Am. Coll. Cardiol. 36, 479-486
203. Armstrong, P.W., Lorell, B.H., Nissen, S. and Borer, J. (2002) Omapatrilat. Circulation 106, e9011-e9012
204. Mistry, N.B., Westheim, A.S. and Kjeldsen, S.E. (2006) The angiotensin receptor antagonist valsartan: a review of the literature with a focus on clinical trials. Expert Opin. Pharmacother. 7, 575-581
205. Ksander, G.M., Ghai, R.D., de Jesus, R., Diefenbacher, C.G., Yuan, A., Berry, C., Sakane, Y. and Trapani, A. (1995) Dicarboxylic acid dipeptide neutral endopeptidase inhibitors. J. Med. Chem. 38, 1689-1700
206. Gu, J., Noe, A., Chandra, P., Al-Fayoumi, S., Ligueros-Saylan, M., Sarangapani, R., Maahs, S., Ksander, G., Rigel, D.F., Jeng, A.Y. et al. (2010) Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). J. Clin. Pharmacol. 50, 401-414
207. Azizi, M., Menard, J., Bissery, A., Guyene, T.T. and Bura-Rivière, A. (2007) Hormonal and hemodynamic effects of aliskiren and valsartan and their combination in sodium-replete normotensive individuals. Clin. J. Am. Soc. Nephrol. 2, 947-955
208. Vaidyanathan, S., Valencia, J., Kemp, C., Zhao, C., Yeh, C.M., Bizot, M.N., Denouel, J., Dieterich, H.A. and Dole, W.P. (2006) Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers. Int. J. Clin. Pract. 60, 1343-1356
209. Solomon, S.D., Zile, M., Pieske, B., Voors, A., Shah, A., Kraigher-Krainer, E., Shi, V., Bransford, T., Takeuchi, M., Gong, J. et al. (2012) The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet 380, 1387-1395
210. McMurray, J.J., Packer, M., Desai, A.S., Gong, J., Lefkowitz, M.P., Rizkala, A.R., Rouleau, J.L., Shi, V.C., Solomon, S.D., Swedberg, K. et al. (2014) Angiotensin-neprilysin inhibition versus enalapril in heart failure. N. Engl. J. Med. 371, 993-1004
211. Green, C.P., Porter, C.B., Bresnahan, D.R. and Spertus, J.A. (2000) Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure. J. Am. Coll. Cardiol. 35, 1245-1255
212. Packer, M., McMurray, J.J., Desai, A.S., Gong, J., Lefkowitz, M.P., Rizkala, A.R., Rouleau, J.L., Shi, V.C., Solomon, S.D., Swedberg, K. et al. (2015) Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation 131, 54-61 Reference deleted
213. Jessup, M. (2014) Neprilysin inhibition-a novel therapy for heart failure. N. Engl. J. Med. 371, 1062-1064
214. Pitt, B., Segal, R., Martinez, F.A., Meurers, G., Cowley, A.J., Thomas, I., Deedwania, P.C., Ney, D.E., Snavely, D.B. and Chang, P.I. (1997) Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 349, 747-52
215. Pfeffer, M.A., McMurray, J.J., Velazquez, E.J., Rouleau, J.L., Køber, L., Maggioni, A.P., Solomon, S.D., Swedberg, K., de Werf, F., White, H. et al. (2003) Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N. Engl. J. Med. 349, 1893-1906
216. Cohn, J.N. and Tognoni, G. (2001) A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N. Engl. J. Med. 345, 1667-1675
217. Young, J.B., Dunlap, M.E., Pfeffer, M.A., Probstfield, J.L., Cohen-Solal, A., Dietz, R., Granger, C.B., Hradec, J., Kuch, J., McKelvie, R.S. et al. (2004) Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials. Circulation 110, 2618-26
218. Klaiber, M., Kruse, M., Völker, K., Feil, R., Freichel, M., Gerling, A., Feil, S., Dietrich, A., Londoño, J.E., Baba, H.A. et al. (2010) Novel insights into the mechanisms mediating the local antihypertrophic effects of cardiac atrial natriuretic peptide: role of cGMP-dependent protein kinase and RGS2. Basic Res. Cardiol. 105, 583-595
219. Langenickel, T.H. and Dole, W.P. (2012) Angiotensin receptor-neprilysin inhibition with LCZ696: a novel approach for the treatment of heart failure. Drug Discov. Today Ther. Strateg. 9, e131-e139
220. Kim, D., Aizawa, T., Wei, H., Pi, X., Rybalkin, S.D., Berk, B.C. and Yan, C. (2005) Angiotensin II increases phosphodiesterase 5A expression in vascular smooth muscle cells: a mechanism by which angiotensin II antagonizes cGMP signaling. J. Mol. Cell. Cardiol. 38, 175-84
221. Frantz, S., Klaiber, M., Baba, H.A., Oberwinkler, H., Völker, K., Gaßner, B., Bayer, B., Abeßer, M., Schuh, K., Feil, R. et al. (2013) Stress-dependent dilated cardiomyopathy in mice with cardiomyocyte-restricted inactivation of cyclic GMP-dependent protein kinase I. Eur. Heart. J. 34, 1233-1244
222. Granger, C.B., McMurray, J.J., Yusuf, S., Held, P., Michelson, E.L., Olofsson, B., Ostergren, J., Pfeffer, M.A. and Swedberg, K. (2003) Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-alternative trial. Lancet 362, 772-776 Reference deleted
223. Williams, B., Cockcroft, J.R., Kario, K., Zappe, D.H., Cardenas, P., Hester, A., Brunel, P. and Zhang, J. (2014) Rationale and study design of the Prospective comparison of Angiotensin Receptor neprilysin inhibitor with Angiotensin receptor blocker MEasuring arterial sTiffness in the eldERly (PARAMETER) study. BMJ Open 4, e004254